Chinese Boai NKY Pharmaceuticals invests in Swedish medtech company NeoDynamics

In Sweden around 8000 women are diagnosed with breast cancer every year, globally this number is 1,7 million women – and the number is increasing. More and more women have their breast cancer detected early as imaging instruments improve and screening programs are established. The improvement of procedures and precision medicine within the breast cancer area adds new challenging requirements on diagnostic methods with respect to precision. When a suspicious change in tissue is detected – the physician typically performs a needle biopsy followed by a pathology investigation to confirm the nature of the change and a correct diagnosis.

NeoDynamics, in support of the above mentioned development within the breast cancer area, has developed a new needle placement technology and a novel needle design to better meet the need for precision during tissue sampling procedures. NeoNavia is designed to support the physician in safely placing the needle, acquiring representative samples with precision irrespective of tissue characteristics as well as size and location of the suspicious lesion.

Anna Eriksrud, CEO:

-To facilitate the diagnosis and treatment of breast cancer patients can result in both cost savings and a better patient experience, CEO Anna Eriksrud, NeoDynamics.

Jörgen Vrenning, CFO:

-The company is now ready to bring its biopsy technology to market after years of development. We have a great product and a strong new shareholder in Boai NKY Pharmaceuticals, who can provide valuable contacts and good insights to the Chinese market, says Jörgen Vrenning CFO, NeoDynamics.